Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Graves' ophthalmopathy with diclofenac or simvastatin
2015-004334-99Phase 2Active
- Sponsor
- Department of Endocrinology
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of diclofenac and simvastatin in Graves' ophthalmopathy (TED) (3 arms), sponsored by Department of Endocrinology. Primary endpoint: Clinical activity score at 6 months and progression to severe Graves' ophthalmopathy. Started Nov 2015; status: active.
02
Drugs
diclofenacsimvastatin
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2015-004334-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004334-99.